bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Reuters

Scientists are opening a new front in the war on cancer with plans to develop “anti-evolution” drugs to stop tumour cells from developing resistance to treatment.
Britain’s Institute of Cancer Research (ICR), one of the world’s top cancer centres, said on Friday its initiative was the first to have at its heart the target of overcoming cancer evolution and drug resistance.
In the same way that bacteria evolve resistance to antibiotics, cancer cells also change to evade the medicines used to fight them, leading to “survival of the nastiest”.
Coffee doesn’t raise cancer risk unless it’s drunk ‘too hot’, UN researchers say
As a result, most cancer drugs eventually stop working, causing patients to relapse.
There are signs, however, that drugs can be developed to tackle this problem, while advances in immunotherapy may also make it possible to direct patients’ immune systems to adapt in response to cancer changes.
Over the next five years, the ICR aims to discover at least one new drug targeting a novel evolutionary mechanism and a new immunotherapy.
While doctors have known about cancer drug resistance for decades, it is only now, with advances in genetics and the development of ultra-fast DNA sequencing, that scientists are unravelling the factors driving the process.

“We now have an incredibly precise understanding of the genetic basis for resistance,” said ICR Chief Executive Paul Workman.
“Over the next five years we will focus all our efforts on overcoming this problem ... we need researchers around the world to embrace the challenge.”
Cancer rates for Hong Kong women set to soar
Already an experimental medicine inhibiting the protein Hsp90, which cancer cells use to protect themselves from stress, has shown encouraging results in clinical trials. ICR scientists are also working on an even more important controller of the stress response known as HSF1.
Workman said experiments on HSF1 were still at an early stage but scientists were close to selecting a drug candidate.
The end result is likely be the development of a number of combination treatments to stop cancer evolving, similar to the drug cocktails used to control HIV or tuberculosis.
In addition to understanding biology, a large part of the research effort will be driven by “big data”, through the use of mathematical models to predict the path of cancer evolution from tumour samples.
Tapping into the terabytes of data thrown up by analysing the genetic profiles of tumours is an increasing focus of cancer research worldwide. It is also a central plank of US Vice-President Joe Biden’s “moonshot” initiative aimed at finding cures for cancer.


Scientists hunt ‘anti-evolution’ drugs in new cancer fight

While doctors have known about cancer drug resistance for decades, it is only now, with advances in genetics and the development of ultra-fast DNA sequencing, that scientists are unravelling the factors driving the process. Photo: TNS

U.S. Vice President Joe Biden smiles as he speaks to guests after a tour of the Victorian Comprehensive Cancer Centre in Melbourne, Sunday, July 17, 2016. (Tracey Nearmy/Pool Photo via AP)

News

World

Europe

Over the next five years, Britain’s Institute of Cancer Research aims to discover at least one new drug targeting a novel evolutionary mechanism and a new immunotherapy
